¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"J Immune Based Ther Vaccines"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® immune system ÇÑ±Û ¸é¿ªÃ¼°è
¼³¸í   
  ¼¼Æ÷¼ººÐ ¹× ºÐÀÚ¼ººÐÀÇ º¹ÇÕü°è·Î¼­, ÀÌÀÇ ÀÏÂ÷±â´ÉÀº ÀÚ±â(self)¸¦ ºñÀÚ±â(not self)·ÎºÎÅÍ ±¸º°ÇÏ°í ¿ÜºÎ»ý¹° ¶Ç´Â ¹°Áú¿¡ ´ëÇØ ¹æ¾îÇϴ °ÍÀÌ´Ù. ÀÏÂ÷ÀûÀΠ¼¼Æ÷¼ººÐÀº ¸²ÇÁ±¸¿Í Å«Æ÷½Ä¼¼Æ÷À̸ç ÀÏÂ÷ÀûÀΠºÐÀÚ¼ººÐÀº Ç×ü¿Í ¸²Æ÷Ä«ÀÎÀÌ´Ù.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • evidence-based medicine
    Áõ°ÅÁß½ÉÀÇÇÐ, Áõ°Å¹ÙÅÁÀÇÇÐ
  • evidence-based practice
    Áõ°ÅÁß½ÉÁø·á, Áõ°Å¹ÙÅÁÁø·á
  • egg-based medium
    ´Þ°¿±âÃʹèÁö
  • fornix-based conjunctival flap
    ¿ø°³°á¸·ÆÇ
  • limbus-based conjunctival flap
    À±ºÎ°á¸·ÆÇ
  • problem based learning
    ¹®Á¦¹ÙÅÁÇнÀ
  • resource based relative value scale
    ÀÚ¿ø±âÁØ»ó´ë°¡Ä¡µî±Þ
  • acquired immune deficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • circulating immune complex
    ¼øÈ¯¸é¿ªº¹ÇÕü
  • drug-induced immune complex
    ¾à¹°À¯¹ß¸é¿ªº¹ÇÕü
  • human rabies immune globulin
    »ç¶÷¹ÌÄ£°³º´¸é¿ª±Û·ÎºÒ¸°, »ç¶÷±¤°ßº´¸é¿ª±Û·ÎºÒ¸°
  • immune
    ¸é¿ª-
  • immune adherence
    ¸é¿ªºÎÂø
  • immune adherence hemagglutination
    ¸é¿ªºÎÂøÀûÇ÷±¸ÀÀÁý
  • immune adherence reaction
    ¸é¿ªºÎÂø¹ÝÀÀ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • problem based learning
    ¹®Á¦¹ÙÅÁÇнÀ
  • immune thrombocytopenic purpura
    ¸é¿ªÇ÷¼ÒÆÇ°¨¼ÒÀÚ»ö¹Ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fornix-based conjunctival flap
    ¿ø°³°á¸·ÆÇ
  • limbus-based conjunctival flap
    À±ºÎ°á¸·ÆÇ
  • resource based relative value scale
    Áö¿ø±âÁØ»ó´ë°¡Ä¡
  • acquired immune deficiency
    ÈÄõ¸é¿ª°áÇÌ
  • acquired immune deficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • ancillary immune system
    º¸Á¶¸é¿ª°è
  • immune adherence
    ¸é¿ªºÎÂø
  • immune bacteriolysis
    ¸é¿ª¼¼±Õ¿ëÇØ
  • circulating immune complex
    Ç÷Á߸鿪º¹ÇÕü
  • drug-induced immune complex
    ¾àÁ¦À¯¹ß¸é¿ªº¹ÇÕü
  • immune complex
    ¸é¿ªº¹ÇÕü
  • immune conglutinin
    ¸é¿ª±³Âø¼Ò
  • immune cytolysis
    ¸é¿ª¼¼Æ÷¿ëÇØ
  • immune deficiency
    (¢¡immunodeficiency) ¸é¿ª°áÇÌ
  • immune deposit
    ¸é¿ªÄ§Âø¹°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gadolinium (Gd) based contrast agent
    °¡µ¹¸®´½ Á¶¿µÁ¦
  • Acquiered immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª °áÇÌÁõÈıº
  • Immune complex
    ¸é¿ªº¹ÇÕü(Øóæ¹ÜÜùêô÷)
  • Immune system
    ¸é¿ªÃ¼°è(Øóæ¹ô÷ͧ)
  • Rh immune globulin
    Rh ¸é¿ª±Û·Îºí¸°
  • acquired immune deficiency
    ÈÄõ¼º ¸é¿ª°áÇÌ
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌÁõÈıº(ý­ô¸àõ Øóæ¹ÌÀù¹ñøý¦ÏØ)
  • aids=£¾acquired immune deficiency syndrome
    ÈÄõ¼º¸é¿ª°áÇÌÁõÈıº(ý­ô¸àõØóæ¹ÌÀù¹ñøý¦ÏØ)
  • anti-immune body
    Ç׸鿪ü.
  • globulin, immune
    ¸é¿ª±Û·ÎºÒ¸°
  • globulin, immune serum
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°
  • hemagglutination, immune adherence
    ¸é¿ªºÎÂø Ç÷±¸ÀÀÁý
  • hemolysis, immune
    ¸é¿ª¿ëÇ÷
  • human serum immune globulin
    Àΰ£Ç÷û¸é¿ª±Û·ÎºÒ¸°.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fornix-based conjunctival flap
    ¿ø°³(±âÀú)°á¸·Æí
  • gadolinium (Gd) based contrast agent
    °¡µ¹¸®´½ Á¶¿µÁ¦
  • limbus-based conjunctival flap
    À±ºÎ(±âÀú)°á¸·Æí
  • resource based relative value scale(RBRVS)
    Áö¿ø±âÁØ »ó´ë°¡Ä¡, ÀÇ·á¼ö°¡ Ã¥Á¤ÀÇ Åä´ë·Î Ȱ¿ëµÊ.
  • resource-based relative value system
    ÀÚ¿ø¿¡ ±Ù°ÅÇÑ »ó´ëÀû °¡Ä¡Ã¼°è
  • tumor immunity,antibody-based therapy
    Ç×ü¿¡ ÀǰÅÇÑ Ä¡·á
  • acquired immune deficiency
    ÈÄõ¼º ¸é¿ª°áÇÌ
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌÁõÈıº(ý­ô¸àõ Øóæ¹ÌÀù¹ñøý¦ÏØ)
  • aids=£¾acquired immune deficiency syndrome
    ÈÄõ¼º¸é¿ª°áÇÌÁõÈıº(ý­ô¸àõØóæ¹ÌÀù¹ñøý¦ÏØ)
  • ancillary immune system
    º¸Á¶Àû ¸é¿ª°è
  • anti-immune body
    Ç׸鿪ü.
  • bacteriolysis, immune
    ¸é¿ª¼º ¼¼±Õ¿ëÇØ
  • circulating immune complex (CIC)
    Ç÷Á߸鿪º¹ÇÕü
  • clearance, immune
    ¸é¿ª¸Å°³Á¦°Å
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Immune cause (Hemolytic anemia)
    ¸é¿ª¿øÀÎ(¿ëÇ÷¼ººóÇ÷)
    [¿¾ ¿ë¾î] ¸é¿ª¼º¿øÀÎ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hemolytic immune body
    ¿ëÇ÷ ¸é¿ªÃ¼(éÁúìØóæ¹ô÷)
  • immune adherence
    ¸é¿ª ºÎÂø(Øóæ¹Ý¾ó·)
  • immune adsorbent
    ¸é¿ª ÈíÂøÁ¦(Øóæ¹ýåó·ð¥)
  • immune antibody
    ¸é¿ª Ç×ü(Øóæ¹ù÷ô÷)
  • immune clearance
    ¸é¿ª ûÁ¤(Øóæ¹ôèïä)
  • immune competent cell
    ¸é¿ª Àû°Ý ¼¼Æ÷(Øóæ¹îêÌ«á¬øà)
  • immune complex
    ¸é¿ª º¹ÇÕü(Øóæ¹ÜÜùêô÷)
  • immune conglutination
    ¸é¿ª À¯Âø ¹ÝÀÀ(Øóæ¹ë¨ó·Úãëë)
  • immune conglutinin
    ¸é¿ª(Øóæ¹)ÄÜ±Û·çÆ¼´Ñ
  • immune cytolysis
    ¸é¿ª ¼¼Æ÷¿ëÇØ(Øóæ¹á¬øàéÁú°)
  • immune deficincy disease
    ¸é¿ª °áÇÌ Áúȯ(Øóæ¹ÌÀù¹òðü´)
  • immune elimination
    ¸é¿ª À̹° Á¦°Å(Øóæ¹ì¶Úªð¶ËÛ)
  • immune globulin
    ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • immune lysis
    ¸é¿ª ¿ëÇØ(Øóæ¹éÁú°)
  • immune opsonin
    ¸é¿ª(Øóæ¹) ¿É¼Ò´Ñ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gadolinium based contrast agent
    °¡µ¹¸®´½Á¶¿µÁ¦
  • immune
    ¸é¿ª¼ºÀÇ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
occ ther occupational therapist or therapy
Phys Ther physical therapist or therapy
rad ther radiation therapy
Rec Ther recreational therapy
Resp Ther respiratory therapy
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ABC Activity Based Costing
BCBL Body-cavity-based lymphoma
CBR Case Based Reasoning
CBR Community Based Rehabilitation
CBO community based organization
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • JrId: 30023
    JournalTitle: Journal of immune based therapies and vaccines [electronic resource].
    MedAbbr: J Immune Based Ther Vaccines
    ISSN:
    ESSN:
    IsoAbbr:
    NlmId: 101152206
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • broad based tumor
    ±âÀúºÎ°¡ ³ÐÀº Á¾¾ç
  • broad-based cherry-size
    ±âÀúºÎ°¡ ³ÐÀº ü¸® Å©±âÀÇ
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª °áÇÌ ÁõÈıº
    1. ÇöÀúÇÑ ¸é¿ª °áÇ̰ú ÇÔ²² ±âȸ°¨¿°, ¼Ó¹ß¼º ¾Ï ¹× ½Å°æ°è Áõ¼¼°¡ µ¿¹Ý. ¹ÙÀÌ·¯½º ÀÚü¿¡ ÀÇÇÑ º´º¯°ú ¸é¿ª´É·Â ÀúÇÏ¿¡ µû¸¥ ±âȸ °¨¿° µîÀÇ ÀÌÂ÷Àû º´º¯ÀÇ µÎ °¡Áö·Î ´ëº°. HIV¿¡ ÀÇÇØ ¹ß»ýµÇ´Â ÁúȯÀ¸·Î ½Å°æ°è°¡ Áß¿ä Ç¥ÀûÁß Çϳª. ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ »ç¶÷ÀÇ 40% Á¤µµ°¡ Áúº´ÀÌ ¹ß»ý. ¹ÙÀÌ·¯½ºÀÇ Á÷Á¢ÀûÀÎ ¿µÇâ¿¡ ÀÌÇÑ º´º¯À¸·Î´Â ¸²ÇÁ±¸¼º ¼ö¸·¿°°ú HIV ³ú¿° µîÀÌ ÀÖÀ½. 2. ÈÄõ¼º ¸é¿ª°áÇÌÁõ. Àΰ£ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
  • drug-induced immune complex
    ¾àÁ¦ À¯¹ß¼º ¸é¿ª º¹ÇÕü
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • human rabies immune globulin
    ±¤°ßº´ ¸é¿ª ±Û·ÎºÒ¸°
    °³¿¡°Ô ¹°¸° ÈÄ ±ÕÀÇ ÁøÇàÀ» ¸·±â À§ÇØ Åõ¿©ÇÑ´Ù.
  • human serum immune globulin
    Àΰ£ Ç÷û ¸é¿ª ±Û·ÎºÒ¸°
  • immune
    ¸é¿ª
    1. ü¾× Ç×üÀÇ »ý»ê, ¼¼Æ÷¼º ¸é¿ªÀÇ ¼º¸³, ¶Ç´Â ±× ¾çÀÚ, ȤÀº ¹ÙÀÌ·¯½º °¨¿°¿¡¼­ÀÇ ÀÎÅÍÆä·Ð Ȱ¼º°ú °°ÀÌ ´Ù¸¥ ±âÁ¤ÀÇ °á°ú µî¿¡ ÀÇÇÏ¿© Áúȯ¿¡ ´ëÇÑ ÀúÇ×·ÂÀÌ ³ô¾ÆÁø »óÅÂ. 2. Ç׿ø °ø°Ý¿¡ ÀÇÇÑ Ã¼¾×¼º Ç×ü ¶Ç´Â ¼¼Æ÷¼º ¸é¿ª, ¶Ç´Â ±× ¾çÀÚÀÇ ¼º¸³. 3. ¸é¿ªÇ÷û ±Û·ÎºÒ¸°°ú °°ÀÌ Ç׿ø °ø°Ý¿¡ ´ëÀÀÇÏ¿© »ý»êµÈ °Í. 4. ¸é¿ªÀÌ µÈ °³Ã¼. 5. ƯÀÌÀû ¶Ç´Â ºñƯÀÌÀû ±âÀüÀ» ÅëÇØ °¨¿°¼º Áúȯ¿¡ ´ëÇ×ÇÏ´Â °Í.
  • immune amnesia syndrome
    ¸é¿ª ±â¾ï »ó½Ç ÁõÈıº
  • immune complex
    ¸é¿ª º¹ÇÕü
    Ç׿ø°ú Ç×üÀÇ Æ¯Á¤ °áÇÕ¹°. ¹ÙÀÌ·¯½º³ª ¼¼±Õ µî À̹°ÀÇ Ä¨ÀÔ¿¡ ´ëÇØ¼­ »ýü°¡ »ý»êÇÑ Ç×ü´Â À̹°ÀÎ Ç׿ø°ú °áÇÕÇÏ¿© ¸é¿ª º¹ÇÕü¸¦ ¸¸µç´Ù. À̴ Ž½Ä ¼¼Æ÷³ª º¸Ã¼¸¦ Ȱ¼ºÈ­ÇÏ¿© À̹°ÀÌ ¹«ÇØÇÑ °ÍÀ¸·Î ºÐÇØÇÏ´Â °ÍÀ» µµ¿Í »ýü ¹æ¾î¿¡ µµ¿òÀ» ÁØ´Ù. Á¶Á÷ Àå¾ÖÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¸é¿ª º¹ÇÕ¼º ÁúȯÀ» ÀÏÀ¸Å°±âµµ ÇÑ´Ù.
  • immune complex-mediated
    ¸é¿ª º¹ÇÕü ¸Å°³¼º
  • immune deficiency disease
    ¸é¿ª °áÇÌ Áúȯ, ¸é¿ª °áÇ̺´
    ¸é¿ª °èÅëÀ» ±¸¼ºÇÏ´Â ¿ä¼ÒÀÇ ±â´É Àå¾Ö¿¡ ÀÇÇÏ¿© ÃÊ·¡µÇ´Â Áúȯ ±º.
  • immune electron microscopy
    ¸é¿ª ÀüÀÚÇö¹Ì°æ¹ý
  • immune mechanism
    ¸é¿ª ±âÀü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
mechanism-based inhibitor A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000)
competency-based education Educational programs designed to ensure that students attain prespecified levels of competence in a given field or training activity. Emphasis is on achievement or specified objectives.
(12 Dec 1998)
problem-based learning Instructional use of examples or cases to teach using problem-solving skills and critical thinking.
(12 Dec 1998)
home care services, hospital-based Hospital-sponsored provision of health services, such as nursing, therapy, and health-related homemaker or social services, in the patient's home. (hospital administration terminology, 2d ed)
(12 Dec 1998)
evidence-based medicine The process of systematically finding, appraising, and using contemporaneous research findings as the basis for clinical decisions. Evidence-based medicine asks questions, finds and appraises the relevant data, and harnesses that information for everyday clinical practice. Evidence-based medicine follows four steps: formulate a clear clinical question from a patient's problem; search the literature for relevant clinical articles; evaluate (critically appraise) the evidence for its validity and usefulness; implement useful findings in clinical practice. The term "evidence based medicine" (no hyphen) was coined at mcmaster medical school in canada in the 1980's to label this clinical learning strategy, which people at the school had been developing for over a decade.
(12 Dec 1998)
aids vaccines Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent aids. Some vaccines containing antigens are recombinantly produced.
(12 Dec 1998)
bacterial vaccines Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
(12 Dec 1998)
cancer vaccines Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumour cells as the source of antigens, or using tumour-specific antigens, often recombinantly produced.
(12 Dec 1998)
vaccines Vaccines are microbial preparations of killed or modified microorganisms which can stimulate an immune response in the body in order to prevent future infection with similar microorganism. The smallpox vaccine has totally eliminated the smallpox disease from our planet.
(12 Dec 1998)
vaccines, attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.
(12 Dec 1998)
vaccines, combined Two or more vaccines in a single dosage form.
(12 Dec 1998)
vaccines, conjugate Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognised by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
(12 Dec 1998)
vaccines, DNA Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
(12 Dec 1998)
vaccines, inactivated Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
(12 Dec 1998)
vaccines, synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • zero-based
    Á¦·Îº£À̽ºÀÇ
  • based
    ±Ù°Å°¡ ÀÖ´Â...;¿¡ ±âÁö(±â¹Ý)¸¦ µÐ
  • character-based
    ¹®ÀÚ ´ÜÀ§ Ç¥½Ã ¹æ½ÄÀÇ
  • computer-based learning
    ÄÄÇ»Å͸¦ ÇнÀÀÇ µµ±¸·Î ÀÌ¿ëÇϱâ
  • immune
    ¸é¿ªÀÇ
  • immune
    ¸é¿ªÀÇ;(Àü¿°º´,º´µ¶µîÀ»)¸éÇÑ;¸é¿ª¼ºÀÇ(to,from);(°ú¼¼,°ø°Ý µî¿¡¼­);¸éÁ¦µÈ(exempt);(..À») ´çÇÒ ¿°·Á°¡ ¾ø´Â(from,against);(¿¡)µ¿ÇÏÁö ¾Ê´Â;¿µÇâÀ» ¹ÞÁö ¾Ê´Â(to);¸é¿ª(¸éÁ¦)ÀÚ
  • immune body
    ¸é¿ªÃ¼;Ç×ü(antibody)
  • immune complex
    ¸é¿ª º¹ÇÕü
  • immune response
    ¸é¿ª ÀÀ´ä;¸é¿ª ¹ÝÀÀ
  • immune serum
    ¸é¿ª Ç÷û
  • immune surveillance
    IMMUNOLOGICAL SURVEILLANCE
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á